Lumida
/HEAL
⌘K
HEAL

HEAL

HEAL
$27.44USD-2.49%-0.70 today

MARKET CAP

0

P/E (TTM)

FWD P/E

DAY RANGE

$27 – $28

52W RANGE

$23
$34

AI Summary

Stalk
Buy NowMedium

HEAL remains in a Stage 2 advancing regime with clear higher highs and higher lows supported by rising EMAs and the 50 DMA. The recent Bullish Exhaustion pattern indicates waning upside momentum, but the pullback is resolving as corrective and holding at the 9/21 EMA zone. Neutral overbought/oversold context and favorable volume dynamics support measured entries, making buying the dip into rising EMAs aligned with medium-term structure and momentum.

  • HEAL AUM ~$30.4M provides diversified exposure to health tech innovators
  • Top holdings like IQVIA and DexCom support robust revenue growth
  • YTD NAV down 9.4% underscores recent underperformance
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

The Global X HealthTech ETF (HEAL) is an investment vehicle focusing on innovative companies within the healthcare sector that leverage technology to improve health outcomes. Launched on July 29, 2020, HEAL aims to capitalize on the growing intersection of healthcare and technology, particularly in areas such as artificial intelligence and robotics. The ETF consists of a diversified portfolio of companies engaging in health technology applications, and its top holdings include prominent names like Oscar Health, Pro Medicus Ltd, IQVIA Holdings, Hims & Hers Health, and DexCom. With current assets under management of approximately $30.42 million, HEAL reflects a significant theme in the ongoing advancement and transformation of healthcare systems globally.

Bull says

  • HEAL AUM ~$30.4M provides diversified exposure to health tech innovators
  • Top holdings like IQVIA and DexCom support robust revenue growth
  • NAV rose 10.1% last month after 9.4% YTD decline
  • 0.25% dividend yield offers income amid price volatility
  • Health tech demand driven by AI, robotics, aging populations
  • High earnings yield and strong momentum factors signal upside

Bear says

  • YTD NAV down 9.4% underscores recent underperformance
  • Lack of fresh catalysts signals potential investor disinterest
  • Sector volatility and tech-selloff pose ongoing downside risk
  • Concentrated top holdings amplify single-stock risk
  • High health tech valuations require strong revenue growth to sustain
  • Elevated leverage risk and high short interest pressure price

Investment themes with HEAL

Medical Devices +0.44%

Devices and instruments for medical treatment

MEDP · RDNT · OPCH
Others +0.32%

Miscellaneous or uncategorized companies

ATAI · SVIX · SVXY